CNBX Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $130.1K | $410.2K | $30.0K | $0 | $7.2K | $9.8K | $9.6K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $0 | $194.8K | $431.6K | $1.2M | $1.8M | $1.7M | $1.5M | $1.0M |
| SG&A Expense | $271.7K | $518.4K | $910.0K | $1.8M | $828.6K | $1.3M | $1.5M | $2.4M |
| Operating Income | $-271.7K | $-583.1K | $-931.4K | $-3.0M | $-2.6M | $-3.0M | $-3.3M | $-3.8M |
| Operating Margin | — | -448.3% | -227.1% | -9,860.4% | — | -42,524.1% | -33,563.0% | -39,670.1% |
| Interest Expense | $39.8K | — | — | — | — | — | — | $852 |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-314.0K | $-695.2K | $-3.7M | $-3.7M | $-3.2M | $-7.5M | $1.1M | $-3.8M |
| Net Margin | — | -534.5% | -904.6% | -12,428.2% | — | -104,337.9% | 11,510.4% | -39,335.7% |
| EPS (Basic) | $0.00 | $-0.02 | $-0.14 | $-0.17 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $-0.02 | $-0.14 | $-0.17 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 90.6M | 30.2M | 26.5M | 25.7M | 2.91B | 2.84B | 2.82B | 2.77B |
| Shares Outstanding (Diluted) | 90.6M | 30.2M | 26.5M | 25.7M | 2.91B | 2.84B | 2.82B | 2.77B |
| Dividends Per Share | — | — | — | — | — | — | — | — |